Passage Bio, Inc.

In the quarter to June 2026, EPS grew 17.6% and free cash flow fell 59.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

3.48 0.12 −3.33%

Follow PASG

Alert me

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
ROE Full definition →	(169.09%)	(128.90%)	(113.78%)	(87.18%)	+8 more TTM periods Free account
ROA Full definition →	(69.20%)	(61.53%)	(55.28%)	(48.69%)
ROIC Full definition →	0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets Full definition →	(810.41%)	(243.65%)	(158.14%)	(117.13%)
Free Cash Flow per Share Full definition →	(10.43)	(9.37)	(9.56)	(10.17)
Free Cash Flow Full definition →	(33.48)	(30.04)	(30.34)	(32.32)
Capital Expenditures Full definition →	0.02	0.61	1.17	1.16
Other line items
Cash ROIC Full definition →	(117.02%)	(66.63%)	(46.63%)	(38.52%)
Accounts Payable Turnover Full definition →	0.00	0.00	0.00	0.00
Average Days of Payables Full definition →	0.00	0.00	0.00	0.00
Tax Rate Full definition →	0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Operating CF/Net income Full definition →	0.93	0.81	0.69	0.74
Depreciation/Fixed assets Full definition →	0.00	0.79	0.21	0.20
Capex/Depreciation Full definition →	0.04	0.92	1.37	1.12
Revenue per Share Full definition →	0.00	0.00	0.00	0.00
Operating CF per Share Full definition →	(10.44)	(9.56)	(9.93)	(10.53)
Capex per Share Full definition →	0.01	0.19	0.37	0.36
Capex to Sales Full definition →	0.00	0.00	0.00	0.00

Columns are period end dates